On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations.
The company, last month, agreed to acquire V-Wave for an upfront payment of $600 million, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion.
With the recent buzz around Johnson & Johnson, some investors may be eyeing potential gains from the company's dividends too. As of now, Johnson & Johnson offers an annual dividend yield of 3.01%. That’s a quarterly dividend amount of $1.24 per ...
